Wednesday, May 30, 2007
Will Avandia's Pitfalls Affect Zimulti's Approval?
Rumblings throughout the Pharma industry and Wall Street are predicting that the recent setback of Avandia (a diabetes drug produced by GSK) will adversely affect the anticipated approval of Zimulti in the United States this summer.
The FDA has a history of allowing current events and isolated incidents to sway their decisions, especially since Zimulti and Avandia (though not the same drug classification and treatment class) can both be considered 'Metabolic Syndrome' type drugs.
Time will tell... I just hope that the historical facts presented on June 13th are the deciding factor for the anticipated late July approval date, not the 'buzz' of current events.
The FDA has a history of allowing current events and isolated incidents to sway their decisions, especially since Zimulti and Avandia (though not the same drug classification and treatment class) can both be considered 'Metabolic Syndrome' type drugs.
Time will tell... I just hope that the historical facts presented on June 13th are the deciding factor for the anticipated late July approval date, not the 'buzz' of current events.
Subscribe to Posts [Atom]
